source
- Kodiak Sciences reports Phase 3 success for Zenkuda, matching Eylea in wet AMDKodiak Sciences announced that its experimental therapy Zenkuda achieved comparable efficacy to the market‑leading anti‑VEGF drug Eylea in a late‑stage trial for wet age‑related macular degeneratio…
- AbbVie receives FDA approval for Parkinson’s drug Juvmo, a Cerevel acquisition assetAbbVie has secured FDA approval for tavapadon, marketed as Juvmo, for the treatment of Parkinson’s disease in adults. The decision follows positive results from the Phase 3 TEMPO trial. In the piv…